olendalizumab (ALXN1007) / AstraZeneca - LARVOL DELTA

A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. (PubMed, Bone Marrow Transplant) - "Neither baseline complement levels (except for C5), activity, nor inhibition of C5a with ALXN1007 correlated with GVHD severity or responses. Further studies are needed to evaluate the role of complement inhibition in GVHD treatment."

Journal • P2 data • Acute Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology

European Commission grants Orphan Drug Designation to ALXN1007 for the treatment of patients with graft-versus-host disease (GVHD) (Businesswire) - "Alexion Pharmaceuticals...announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007...for the treatment of graft-versus-host disease..."

Orphan drug • Graft versus Host Disease

Alexion: Q2 FY 2016 Results (Alexion) - "Historical overall response rate 56% at 28 days"; "Historical CR rate 49% at 28 days"

P2 data • Graft versus Host Disease